Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pulmonary diffusing capacity measured by NO/CO transfer in Tunisian boys

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lung compartment analysis assessed from N2 multiple-breath washout in children with cystic fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The impact of mannose-binding lectin polymorphisms on lung function in primary ciliary dyskinesia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early IL-2 treatment of mice with Pseudomonas aeruginosa pneumonia induced PMN-dominating response and reduced lung pathology

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Improving antibiotic treatment of bacterial biofilm by hyperbaric oxygen therapy: Not just hot air

    Research output: Contribution to journalReviewpeer-review

  5. In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The upper airways (UAW) are a niche and a reservoir of Pseudomonas aeruginosa strains that cause chronic infection of the lower airways (LAW) in cystic fibrosis (CF). Here, we assessed the role of anti-P. aeruginosa immunoglobulin A (IgA) and IgG antibodies in upper and lower airway infections in cystic fibrosis patients.

METHODS: Nasal lavage fluid and induced sputum samples of 40 CF patients were microbiologically cultured. We searched for correlations between anti-P. aeruginosa IgA and IgG levels, measured by enzyme-linked immunosorbent assay (optical density), and unspecific immune mediators in both specimens.

RESULTS: Anti-P. aeruginosa IgA (median optical density: 0.953 vs 0.298) and IgG (0.120 vs 0.059) were significantly higher in nasal lavage than in sputum, but not significantly different between patients with and without chronic P. aeruginosa infection in UAW. Matrix metallopeptidase-9 (MMP-9) in nasal lavage and neutrophil elastase (NE) in sputum were predictors of IgA in nasal lavage and IgA in sputum, respectively. IgA was a predictor of myeloperoxidase (MPO) in nasal lavage. Tissue inhibitor of metalloproteinases-1 (TIMP-1) was a predictor of IgG in sputum. IgG, TIMP-1, and NE in sputum were predictors of IgG in nasal lavage.

CONCLUSION: The anti-P. aeruginosa IgA response was more prominent in CF patients' UAW, indicating a lower degree of inflammatory responses. Proteases may play a role in the anti-P. aeruginosa humoral response in the upper and LAW, and anti-P. aeruginosa IgG may be involved in the crosstalk between upper and lower airways in cystic fibrosis patients.

Original languageEnglish
JournalPediatric Pulmonology
Volume55
Issue number4
Pages (from-to)959-967
Number of pages9
ISSN8755-6863
DOIs
Publication statusPublished - Apr 2020

    Research areas

  • IgA, IgG, Pseudomonas aeruginosa, lower airways, nasal, upper airways

ID: 60286062